Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism (Q35928257)

11 August 2017

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism (English)

1 reference

11 August 2017

1

Bo Ahrén

1 reference

11 August 2017

James E Foley

2

1 reference

11 August 2017

19 February 2016

1 reference

11 August 2017

1 reference

11 August 2017

59

1 reference

11 August 2017

5

1 reference

11 August 2017

907-917

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-016-3899-2

11 August 2017

0 references

cites work

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Insulin rather than glucose homoeostasis in the pathophysiology of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

A review of gliptins for 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

DPP-4 inhibitors: focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

β-Cell function in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

An examination of beta-cell function measures and their potential use for estimating beta-cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Glucagon--Early breakthroughs and recent discoveries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of vildagliptin on hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

New insights into the pathophysiology of dyslipidemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3899-2

Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

21 January 2018

1 reference

12 December 2020

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study

1 reference

12 December 2020

DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice

1 reference

12 December 2020

Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

1 reference

12 December 2020

The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose

1 reference

12 December 2020

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

12 December 2020

Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy

1 reference

12 December 2020

10.1007/S00125-016-3899-2

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

26894277